Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Gross Margin (2021 - 2025)

Tg Therapeutics (TGTX) has 5 years of Gross Margin data on record, last reported at 80.19% in Q4 2025.

  • For Q4 2025, Gross Margin fell 557.0% year-over-year to 80.19%; the TTM value through Dec 2025 reached 83.66%, down 464.0%, while the annual FY2025 figure was 83.66%, 464.0% down from the prior year.
  • Gross Margin reached 80.19% in Q4 2025 per TGTX's latest filing, down from 82.63% in the prior quarter.
  • Across five years, Gross Margin topped out at 97.88% in Q3 2023 and bottomed at 80.19% in Q4 2025.
  • Average Gross Margin over 5 years is 87.65%, with a median of 87.63% recorded in 2023.
  • Peak YoY movement for Gross Margin: crashed -1411bps in 2023, then surged 363bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 82.47% in 2021, then rose by 17bps to 96.25% in 2022, then fell by -15bps to 82.14% in 2023, then grew by 4bps to 85.77% in 2024, then dropped by -6bps to 80.19% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 80.19% in Q4 2025, 82.63% in Q3 2025, and 86.58% in Q2 2025.